The Lone Analyst Who Said Sell Valeant When Hedge Funds Piled In

  • Khmelnitsky watched shares double in a year, before crashing
  • `I stayed with the call,' Veritas analyst says in interview

Valeant CEO Makes His Case Right to Analysts

In July 2014, Dimitry Khmelnitsky advised investors to sell Valeant Pharmaceuticals International Inc. and then watched the stock double in a year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.